OxSonics™ Raises £10.5m in Oversubscribed Series B2 Equity Financing
OxSonics Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer today announced closure of a £10.5m Series B2 financing round.
"..a truly amazing result, to be judged the winner amongst so many healthtech companies across Europe is something to be truly proud of. This success is testament to the highly innovative technology OxSonics is developing and the first-class team at OxSonics.."#TTFinal19#Winner
From over 2,500 companies OxSonics has been judged as the BIG WINNER of the European-wide Healthtech 2019 Tech Tour Contest Final! #TTfinal19#Gold#OxSonics
@FortuneMagazine@OxSonics strongly agrees with this article’s title! However OxSonics Therapeutics is represented incorrectly here; No drugs are contained in bubbles in @OxSonics approach. Far from it! Here is how our platform works: https://t.co/E5dw1GBPNp
@OxSonics Commercial Director @nikolaschalkias will be attending #ASCO2019 in Chicago. An excellent opportunity to network and meet new and existing colleagues. Looking forward to it!